In a recent study entitled “Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis,” a team of researchers investigated the differences in gene expression in fibroblast foci in patients with idiopathic pulmonary fibrosis (IPF). They found that the expression of a particular gene, USP13, was…
Idiopathic Pulmonary Fibrosis: Fibroblasts More Agresssive With USP13 Loss
“Watch this video for some facts on Idiopathic Pulmonary Fibrosis.” Read more about IPF: https://bit.ly/1QiRmr3…
The Pulmonary Fibrosis Foundation (PFF), an organization whose goal is to raise awareness, offer disease education, advance care, and fund research in the field of pulmonary fibrosis (PF), announced in a press release that Genentech, a biotechnology company part of the Roche Group, will assume the role of Founding…
Esbriet is an anti-inflammatory and anti-fibrotic drug that reduces inflammation and fibrosis simultaneously. Learn more: https://bit.ly/Esbriet Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This…
While the therapy was approved for use in 2014 in the US, Japan was the first country to approve its commercial use in 2008, followed by India in 2010, Europe in 2011, and China in 2013. Because IPF is considered a rare condition, this drug was…
“Watch the video shared by the Canadian Pulmonary Fibrosis Foundation to understand what is like to live with IPF through the eyes of patients and their families.” Learn more about Esbriet that addresses Idiopathic Pulmonary Fibrosis: https://bit.ly/Esbriet…
The American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada, included a breakfast symposium where a panel of experts shared practical tips to help clinicians assess, diagnose, and manage idiopathic pulmonary fibrosis (IPF) and co-morbidities linked to the disease. Dr. Timothy Whelan, associate professor…
Boehringer Ingelheim Pharmaceuticals, Inc., recently announced data on the first 49 patients participating in the IPF-PRO (Idiopathic Pulmonary Fibrosis – PROspective Outcomes) Registry, better characterizing the features of patients with IPF when they are diagnosed with the disease. The data was presented at the American College of…
Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015). The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both the efficacy and safety…
Reata Pharmaceuticals, a clinical-stage biopharmaceutical company, recently presented results from the LARIAT trial investigating the drug bardoxolone methyl in patients with pulmonary arterial hypertension (PAH). The study entitled “Bardoxolone Methyl Evaluation in Patients with Pulmonary Arterial Hypertension (PAH)” was presented in the 2015 American College…
